세포은행 아웃소싱 시장 - 예측(2026-2031년)

Cell Banking Outsourcing Market is expected to grow at a 15.02% CAGR, increasing to USD 24.437 billion in 2031 from USD 10.556 billion in 2025.

The cell banking outsourcing market comprises specialized service providers that handle the critical upstream bioprocess activities of developing, characterizing, testing, and storing cell banks under stringent, controlled conditions. This outsourcing model delivers comprehensive services encompassing the establishment of research cell banks (RCBs), master cell banks (MCBs), and working cell banks (WCBs), alongside full analytical characterization, stability testing, and long-term cryogenic storage. The primary goal is to ensure the provision of a consistent, well-documented, and contaminant-free starting material-whether mammalian, insect, or microbial cells-for use in biopharmaceutical production, cell-based therapies, and advanced research. By entrusting this foundational step to experts, clients secure the traceability, viability, and regulatory compliance of their core biological assets.

Market expansion is fundamentally driven by the explosive growth and capital constraints of the biotechnology sector, particularly in advanced therapeutic medicinal products (ATMPs). The primary catalyst is the burgeoning pipeline of cell and gene therapies (CGTs), which are inherently dependent on the reliable and reproducible performance of starting cell materials, including patient-derived or engineered cell lines. For small and mid-sized biotechs, which dominate this innovative space, building internal GMP-compliant cell banking infrastructure represents a prohibitive capital expenditure and a distraction from core R&D. Outsourcing provides a critical path to de-risk development, accelerate timelines, and access specialized technical expertise without massive upfront investment.

A parallel and powerful driver is the intensifying global regulatory scrutiny over cell line history and characterization. Regulatory agencies, including the FDA and EMA, mandate rigorous documentation, comprehensive testing for adventitious agents, and proof of clonality and stability for cell banks used in clinical and commercial production. Specialized Contract Development and Manufacturing Organizations (CDMOs) and dedicated cell banking service providers have established validated platforms and quality systems designed explicitly to meet these complex requirements, offering sponsors a streamlined route to regulatory compliance. This is especially critical as therapies advance toward late-stage clinical trials and commercialization.

Geographically, the Asia-Pacific region is emerging as a significant and high-growth market, propelled by strategic government initiatives. National policies across the region are actively fostering domestic biotech and biopharmaceutical industries through substantial funding, tax incentives, and the development of specialized bioparks. This concerted effort to build regional capacity in advanced therapies is creating a concentrated demand for supporting services, including cell banking. Service providers are establishing or expanding capabilities in APAC to capture this growth and offer geographic proximity to a burgeoning client base.

Despite clear drivers, the market faces a significant and intrinsic constraint: the profound sensitivity surrounding intellectual property (IP) and proprietary cell lines. For biotech companies, a cell line often represents the foundational IP asset of their entire therapeutic platform. The decision to outsource its banking involves transferring this critical biological material and associated data to a third party, raising legitimate concerns over data security, confidentiality, and potential IP leakage. Building trust through robust legal agreements, transparent processes, and demonstrable security protocols is paramount for service providers. This concern can slow adoption or lead sponsors to seek hybrid models where the most sensitive steps are kept in-house.

The competitive landscape features a mix of large, global CDMOs with integrated cell banking services and smaller, niche providers specializing exclusively in advanced cell and gene therapy starting materials. Competition centers on technical differentiation in areas like single-cell cloning technologies, next-generation sequencing for characterization, the ability to handle diverse and complex cell types (e.g., iPSCs, CAR-T cells), and the robustness of quality and regulatory support. Success hinges not only on technical excellence but on becoming a trusted strategic partner, capable of safeguarding a client's most valuable biological assets while navigating the complex path to regulatory approval.

In conclusion, the cell banking outsourcing market is a specialized but essential enabler of the modern biopharmaceutical and advanced therapy ecosystem. Its growth is structurally linked to the rise of capital-efficient biotech innovation and the stringent quality demands of regulators. For industry experts, strategic focus must center on addressing the paramount concern of IP security through ironclad operational and contractual safeguards, while continuously advancing technical capabilities to support next-generation cell therapies. The ability to offer seamless, audit-ready services that ensure both the physical integrity and the legal protection of a client's cell banks will be the defining factor for market leadership. Success in this market means being perceived not merely as a vendor, but as a secure and reliable extension of a client's own research and development operations.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Cell Banking Outsourcing Market Segmentation

• By Bank Type
• Master Cell Bank
• Working Cell Bank
• By Cell Type
• Stem Cell
• Non-Stem Cell
• By End-User
• Pharmaceutical & Biotech Companies
• Academic & Research Institutes
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CELL BANKING OUTSOURCING MARKET BY BANK TYPE

• 5.1. Introduction
• 5.2. Master Cell Bank
• 5.3. Working Cell Bank

6. CELL BANKING OUTSOURCING MARKET BY CELL TYPE

• 6.1. Introduction
• 6.2. Stem Cell
• 6.3. Non-Stem Cell

7. CELL BANKING OUTSOURCING MARKET BY END-USER

• 7.1. Introduction
• 7.2. Pharmaceutical & Biotech Companies
• 7.3. Academic & Research Institutes
• 7.4. Others

8. CELL BANKING OUTSOURCING MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Bank Type
  • 8.2.2. By Cell Type
  • 8.2.3. By End-User
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Bank Type
  • 8.3.2. By Cell Type
  • 8.3.3. By End-User
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Bank Type
  • 8.4.2. By Cell Type
  • 8.4.3. By End-User
  • 8.4.4. By Country
    • 8.4.4.1. Germany
    • 8.4.4.2. France
    • 8.4.4.3. United Kingdom
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Bank Type
  • 8.5.2. By Cell Type
  • 8.5.3. By End-User
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Others
• 8.6. Asia Pacific
  • 8.6.1. By Bank Type
  • 8.6.2. By Cell Type
  • 8.6.3. By End-User
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. India
    • 8.6.4.3. Japan
    • 8.6.4.4. South Korea
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Thailand
    • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Sartorius AG
• 10.2. Cryosite Limited
• 10.3. Charles River Laboratories Inc.
• 10.4. Cryo-Cell International, Inc
• 10.5. GBI Biomanufacturing
• 10.6. Lonza Group
• 10.7. SGS SA
• 10.8. WuXi AppTec
• 10.9. Eurofins Scientific
• 10.10. SK Pharmteco Inc
• 10.11. Biofortuna Limited

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations